Education
About Us
Working with TipRanks
Follow Us
IBBQ - ETF AI Analysis
Top Page
Invesco Nasdaq Biotechnology ETF (IBBQ)
Rating:65Neutral
Price Target:―
Positive Factors
Recent Performance Momentum
The ETF has shown solid gains over the last three months and a positive trend year-to-date, indicating improving momentum in its biotech holdings.
Low Expense Ratio
The fund charges a relatively low management fee, which helps investors keep more of their returns over time.
Exposure to Innovative Biotech Leaders
Top holdings include well-known biotechnology companies and some strongly performing names, giving investors targeted exposure to drug and therapy innovation.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so the fund is heavily exposed to swings in biotechnology and pharmaceutical markets.
U.S.-Only Geographic Focus
With nearly all holdings in U.S. companies, the ETF offers little geographic diversification and is closely tied to the U.S. market and regulatory environment.
Mixed Performance Among Top Holdings
Several of the largest positions have shown weak or negative performance this year, which could weigh on the fund if these stocks do not recover.
IBBQ vs. SPDR S&P 500 ETF (SPY)
AUM73.77M
RegionNorth America
Expense Ratio0.19%
Beta0.81
IssuerInvesco
Inception DateJun 11, 2021
Dividend Yield0.87%
Asset ClassEquity
Index TrackedNASDAQ / Biotechnology
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume40,526
30 Day Avg. Volume40,345
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.13Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering262
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBBQ Summary
The Invesco Nasdaq Biotechnology ETF (IBBQ) is a fund that follows the Nasdaq Biotechnology Index, focusing on U.S. biotech and life sciences companies within the health care sector. It holds many drug and treatment developers, including well-known names like Amgen and Gilead Sciences. Someone might invest in IBBQ if they want growth potential from new medicines and medical technologies, while spreading their money across many biotech stocks instead of picking just one. A key risk is that biotech shares can be very volatile, so the ETF’s price can swing sharply up or down based on drug trial news and health care policy changes.
How much will it cost me?The Invesco Nasdaq Biotechnology ETF (IBBQ) has an expense ratio of 0.19%, meaning you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it tracks an index rather than requiring frequent adjustments by fund managers.
What would affect this ETF?The Invesco Nasdaq Biotechnology ETF (IBBQ) could benefit from advancements in biotechnology and pharmaceutical innovation, as well as increased global demand for cutting-edge healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or broader economic downturns that could impact funding for biotech firms. Its focus on U.S.-based companies and heavy exposure to the healthcare sector means it is particularly sensitive to changes in government healthcare policies and drug approval processes.
IBBQ Top 10 Holdings
IBBQ is a pure-play U.S. biotech fund, and its story right now is one of big, steady drugmakers trying to offset choppier innovators. Heavyweights like Amgen and Gilead are providing a relatively steady backbone, while Regeneron has been a bright spot over the past few months despite some recent wobbling. On the flip side, Alnylam and Insmed have been lagging, acting like a headwind for the portfolio. Illumina and Revolution Medicines are the more exciting climbers, hinting at how cutting-edge platforms can move the needle in this concentrated health care sleeve.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Gilead Sciences | 9.32% | $6.88M | $176.11B | 45.82% | 78 Outperform | |
| Vertex Pharmaceuticals | 8.93% | $6.60M | $119.22B | -2.13% | 78 Outperform | |
| Amgen | 8.19% | $6.05M | $184.10B | 19.26% | 77 Outperform | |
| Regeneron | 5.88% | $4.35M | $77.93B | 8.32% | 78 Outperform | |
| Alnylam Pharma | 3.38% | $2.50M | $44.66B | 25.13% | 60 Neutral | |
| Insmed | 2.48% | $1.83M | $33.46B | 90.08% | 43 Neutral | |
| Biogen | 1.98% | $1.46M | $26.39B | 25.69% | 74 Outperform | |
| Argenx Se | 1.83% | $1.35M | $51.45B | 27.09% | 79 Outperform | |
| Illumina | 1.63% | $1.20M | $22.13B | 13.63% | 71 Outperform | |
| United Therapeutics | 1.54% | $1.14M | $20.21B | 34.40% | 79 Outperform |
IBBQ Technical Analysis
Positive
―
Price Trends
28.73
Positive
27.11
Positive
24.34
Positive
Market Momentum
0.25
Positive
54.77
Neutral
45.41
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBBQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.20, equal to the 50-day MA of 28.73, and equal to the 200-day MA of 24.34, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 54.77 is Neutral, neither overbought nor oversold. The STOCH value of 45.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBBQ.
IBBQ Peer Comparison
Comparison Results
Performance Comparison
IBBQ
Invesco Nasdaq Biotechnology ETF
29.38
6.96
31.04%
XHS
SPDR S&P Health Care Services ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents